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Bioanalytical automation expanded at Glaxo Inc. from 1987 to
1991 by cycling through periods of justification, planning,
implementation, obstacle-jumping and success, which justified
continued cycling. In 1990 it became evident that the technology and
its growth needed to be planned and the resources had to be
managed. A Strategic Plan was researched andprepared. The plan
describes the mission, values, goals and structure ofthe Bioanalyti-
cal Automation Group and the most important requirements for
achieving those planned goals, including: (1) Long-term manage-
ment commitment; (2) Trained, dedicated personnel; (3) Quality
facilities; (4) Teamwork; and (5) Investment in automation-
compatible equipment. The strategicplan has been in effectfor over
ayear; current status, history, and thefuture are discussed in this
article.
Introduction
The Bioanalytical Robotics laboratory at Glaxo Inc. has
continually progressed through a series of justification,
planning, implementation, obstacle-jumping and success
during its development. Within those cycles there have
been many smaller cycles tojustify purchases, headcount,
workload and deadlines, but the five major cycles have
been the driving force in terms of ability to grow, be
successful and provide the senior management commit-
ment needed to negotiate resources. The laboratory is
currently in the fifth major cycle of growth.
These major cycles are described here in detail, leading
up to the formal strategic plan that is now used to pace
growth and to adjust to unforeseen obstacles and needs.
The Clinical Pharmacology Department currently com-
prises two sections: Pharmacokinetics and Bioanalytical.
The Pharmacokinetics Section is the primary customer of
the Bioanalytical Section; other customers of Bioanalyti-
cal include Medical, Pharmaceutics, Toxicology and
Glaxo UK. Most of Bioanalytical’s work provides service
to the Pharmacokinetics Section- drug project teams are
formed with this section to work on clinical projects
supporting Phases I to IV of drug development.
The Bioanalytical Section of Clinical Pharmacology
comprises four subgroups: Biopharmaceutics, Method
Development, Contract Analytical and Robotics, each
with its own manager. Staff are cross-trained between the
subgroups and they can rotate between them for career
development. All of the groups engage in some form of
method development. Contract Analytical externally
completes about 30% of Bioanalytical’s work, about 10-
20% is completed manually in-house and the rest, over
half, is done in robotics. Three years ago about 70% of
Bioanalytical’s work was contracted out, compared with
about 30% today.
In Bioanalytical Robotics there are four fully automated
robotic systems that primarily perform solid phase
extraction with on-line HPLC analysis. The Group has
liquid-liquid extraction and protein precipitation extrac-
tion capability, but assays are developed and validated
using solid phase extraction because it is the most robot-
compatible way to clean up human serum and urine.
Chemists and university consultants with solid phase
extraction expertise are employed to help develop quality
solid phase extraction procedures so that they can be
easily automated. The HPLC systems are on-line,
sometimes with two HPLCs per robot to increase
throughput. The robots can monitor and control their
HPLC statuses and other conditions as needed.
The present
Glaxo Inc. is the US member of the UK-based multi-
national company, Glaxo Holdings. There are 41 000
employees in its 70 world-wide companies. The US
operation is the second largest Glaxo company, with 4600
staff. Worldwide, Glaxo has at least 16 full laboratory
robot systems; 12 of those systems are at Glaxo Inc. in
North Carolina.
Glaxo Inc. has three laboratory robotics groups, includ-
ing (1) a group in QA/QC with four fully automated
robot systems and a variety of different types of
workstations; (2) a group in Analytical Chemistry, with
three robotic systems; and (3) the Bioanalytical Robotics
group in the Clinical Pharmacokinetics Department, the
focus of this paper.
The four Bioanalytical robots are all Zymark PyTech-
nology systems (Zymark Corporation, Hopkinton, Mas-
sachusetts): one purchased in 1989, solely analyses
ranitidine; a Zymate XP robot works in parallel in drug
development with a robot at a Glaxo UK facility; a 1990
system is used for method development and work
overflow of various drugs; and the fourth, purchased in
1987, which analyses five different drugs, is used for
method development using experimental design software
and will soon be fitted with equipment and software to
function as an Expert System with HPLC/solid phase
extraction method design and development capability.
There are three full-time scientists and one manager
working in Bioanalytical Robotics, plus rotational scien-
tists from the other Bioanalytical groups and scientists
from Glaxo UK who come to train in the technology.
(C) Zymark Corporation 1992
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The scientists and the four robots currently analyse 20-
30 000 samples per year, limited primarily by workload
and secondarily by headcount.
Five robotic assays and two assays in automation
development have been validated. The robots undergo
complete assay validation and cross-validation under the
same SOP criteria as manual assay validation and
analytical equipment validation. The justification for the
development and implementation of a robotic assay is
determined by project deadline priority, with FDA
response being the highest priority, followed by NDA
submissions; other prioritization schedules are negotiated
with customers.
The past
Automation began in 1986 as a strategic investment, as
evident by the justifications that management gives for
bringing automation experience into the department and
allowing time for its development:
Table 1. The first growth cycle ofjustification, planning and
success.
Initial
justifications:
Initial plans:
Obstacles:
Successes:
The application was logical
The technology had improved
The employees were burned out
Quality/productivity may be improved
Automation was the future.
Hire an experienced chemist
Contract most work out
Purchase a robot
Train the other scientists
Don’t expect too much.
Technology
Resentment
Fear
Threat.
First assay developed and validated
Comparison with manual assay gave good
results.
(1) Bioanalytical is a local application for automation.
(2) Many of the serious bugs in the technology had been
worked out.
(3) The employees were getting burned out.
(4) It would be interesting to see what it can do for
quality and/or productivity.
(5) Automation was the future and we should get started
soon to be leaders in the effort.
Few plans, other than hiring the chemist and buying a
robot, were made during the two years of development
and few expectations were set upon implementation.
To get from there to where we are now, Bioanalytical
Robotics has repeatedly gone through cycles ofjustifica-
tion, planning, implementation, obstacle-jumping and
success (see figure 1). The cycles are still going on today,
but the individual cycle-times have become shorter each
time more evidence is shown to senior management that
automation achieves its goals.
The first cycle, lasting about two years, started in 1986
when the first automation-experienced analytical chemist
was hired into Bioanalytical (see table 1). That chemist
Figure 1. Continuous growth cycle of Bioanalytical Robotics in
Glaxo Inc.
was given time to develop, automate and validate an
assay. The first year was spent using workstation
technology and the second year using a full Zymate
system. During that dedicated time more than half the
laboratory’s work was contracted out to allow time to
develop automation without burning out the five to six
chemists who then completed the work manually.
The first success came with the validation of a fully-
automated assay to measure ranitidine in serum, followed
by the completion of the first clinical study on a robot.
That first study was analysed manually at a contract
laboratory, then repeated on a robot system with no
difference in the results. After that finding, the robot was
regularly used for analysis of clinical study samples. A
year later another study was completed, both robotically
and manually, and the results were compared using
statistical tests of significance. There was no difference in
accuracy between the methods, and the results from
samples run on the robot showed that the robotic assay is
significantly more precise than the manual assay. Those
results were presented at ISLAR in 1989 [1].
The biggest obstacles during that period were negative
reactions from co-workers doing manual work, including
resentment of the automation chemist who was ’playing
with the robot’, threat of loss ofjob security, loss of assay
ownership and intimidation at the complexity of the
equipment. At the earliest stages of implementation, the
lack of equipment suited to bioanalytical applications
was also an obstacle that was soon overcome by
technological advances in the laboratory automation
industry.
The successes of the first cycle justified the second cycle
during which more definite plans and expectations were
put into place. From the start in 1986 to today there have
been five cycles. They are easiest identified by their major
milestones ofsuccess. Each success helped to justify more
resources, which gave way to new successes (table 2).
Each successive cycle was shorter than the one before it:
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Table 2. Bioanalytical robotics growth cyclesfrom 1987 to present.
Cycle Cycle 2 Cycle 3 Cycle 4 Cycle 5
1987-89 1989-90 1Q90-3Q90 3Q90-1Q91 1Q91-now
Resources
No. ofpeooplel
No. of robots
Lab space
2
Obstacles Technology
Fear
Resentment
Threat
Successes st validation
Repeated study
2 3(+1) 3(-t-1)
2 3 4
4 4 6
Fear Fear Headcount Headcount
Resentment Space Training Training
Threat Data handling Data handling Data handling
Improved quality 2nd validation
1st clinical study 2 throughput
completed
International
cooperation
Strategic Plan
4th validation
5th validation
13 000+ samples
1. Numbers in parentheses indicate visiting scientists.
2. Expressed in units of number of robot systems the space can accommodate.
the first was two years, the second was one year, the third
was about nine months, the fourth was six months and
the fifth has also been about six months. The shortening
in cycle time was primarily due to the increase in senior
management commitment with each success, which
spawned increases in automation headcount, equipment,
workload, space and the other resources essential for
growth of robotics.
Strategic planning
In mid 1990, during the third cycle, management was
confident and committed enough to robotics to formally
plan its future organization, functions and growth. A
strategic plan was then produced for Bioanalytical
Robotics. The intention was to determine and document
where the group was going and what resources would be
needed to get there.
First, the entire department formulated and unanimously
agreed on a mission statement and a set ofvalues for all of
its groups. One of those value statements included
productivity and quality, both ofwhich had by then been
exemplified by robotics. It was then decided that the best
way to write a comprehensive plan for the robotics group
was to conduct research by talking to people with
experience of different stages of laboratory automation
growth. The most valuable source of information turned
out to be the 1990 ISLAR. The justifications, planning
processes, obstacles and resource requirements that other
users experienced during laboratory automation were
compared and the information gathered formed the
backbone of the stategic plan.
The research showed the following experiences of other
robotics groups, regardless of their industries or appli-
cations [2,3,4,5,6]:
The justifications for (successes of) implementing auto-
mation are:
(a) Increased productivity, quality and efficiency.
(b) Safety.
(c) Expanded customer base.
(d) Increased job satisfaction/lower
burnout.
(e) Greater departmental visibility.
(/) Updated technology.
employee
The resources those justifications/successes required are:
(a) Senior management commitment.
(b) Appropriate laboratory facilities.
(c) Trained, dedicated personnel.
(d) Teamwork.
(e) Investment in compatible peripherals.
The obstacles that occurred most frequently are:
(a) Data collection and management limitations.
(b) Employee threat and intimidation.
(c) Space limitations.
All sources of information were emphatic that without
commitment from senior management, the resources are
not attainable, the successes are not achievable, and the
obstacles cannot be overcome.
Another common issue that arose when speaking with
people at ISLAR was that, with the growth of automa-
tion, people take the robots more seriously and anthropo-
morphism ceases. This is not something we have found to
be true- the author’s group takes robot-naming more
seriously than ever and the names are used to identify the
robot systems when away from them, such as in a
meeting.
Also noteworthy from the information collected was that
the successful robot users eventually evolved dedicated,
centralized robotics groups that develop the systems to be
used as turnkey instruments by staff that are inex-
perienced in automation. The author’s group has evolved
from: (1) one person who develops and uses the systems
to (2) a group of people who develop and use them to (3)
setting up some assays that are turnkey for inexperienced
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users from other groups while also running systems as
end-users.
All the above information was compiled and used to write
the strategic plan, which detailed the following infor-
mation for one year and for three years:
(1) Missions and goals.
(2) Functions.
(3) Customers.
(4) Group organizational description.
(5) Workload management.
(6) Resources required (people, equipment, space,
commitment).
(7) Potential barriers.
A more detailed outline is shown in figure 2.
H.
III.
IV.
Departmental Mission, Values and Goals
Mission and goals of Robotics Group
A. Description of Group’s functions
1. Services to be performed
2. Customers, by priority
3. Goals of Group
B. Description of Group
1. Where it will fit into the organization
2. How the Group will be organized
3. How the Group’s workload will be managed
C. Resources required to achieve the goals" of
Strategic Plan
1. Personnel
2. Equipment, software and systems
3. Facilities
4. Intra- and inter-departmental relationships
One-year goals of Group
A. Description of Group
B. Description of one-year goals
1. Steps to be taken to attain resources
2. Steps to be taken to develop customer
relationships
Potential barriers to achieving goals
A. Physical barriers
1. Space
2. Personnel
3. Budget
B. Political barriers
1. Reorganization
2. Commitmentfrom staff and Senior
Management
Figure 2. Strategic plan for Robotics Group.
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The plan has been in effect for over a year. It was
reviewed for update at six months, with no changes
necessary. There will probably be some adjustments to it
in the future.
The future
The group’s work and growth is steady and the specific
resources needed to grow according to the strategic plan
have been selected.
The following technological projects will be pursued in
1992:
(1) Expert systems for intelligent control and method
development.
(2) A software-, hardware, robot- and user-friendly
data acquisition system.
(4) Bar-coding.
(5) Novel sample preparation techniques.
(6) RIA/ELISA.
(7) GC sample preparation.
The following political projects are being worked on:
(1) Technology transfers to and from other Glaxo
groups, domestic and international.
(2) Reorganization, necessitating re-education of a
new line of senior management.
(3) Quality/productivity/efficiency assessment.
(4) Customer base expansion.
References
1. LLOYD, T. L. and LANG, J. R. Robotic vs. manual HPLC
assay: precision and accuracy comparison for ranitidine in
human serum. Advances in Laboratory Automation Robotics
(Zymark Corporation, Hopkinton, Massachusetts, 1990),
73.
2. TAYLOR, G. L., SMITH, T. R. and KAMLA, G. J., Robotics
fulfill a strategic need. Advances in Laboratory Automation
Robotics (Zymark Corporation, Hopkinton, Massachusetts,
1991), 1.
3. KUSHINSKY, S., Managing robotics in the bioanalytical/
metabolic environment of a pharmaceutical company.
Advances in Laboratory Automation Robotics (Zymark Corpor-
ation, Hopkinton, Massachusetts, 1991), 63.
4. ELNENAEY, E. A., PLUSCEC, J. and FERNANDEZ, V. Chal-
lenges facing modern automated laboratories: robotic appli-
cations. Advances in Laboratory Automation Robotics (Zymark
Corporation, Hopkinton, Massachusetts, 1991), 77.
5. HAMILTON, S. D., Managing an automation development
group. Advances in Laboratory Automation Robotics (Zymark
Corporation, Hopkinton, Massachusetts, 1991), 91.
6. PLUMMER, G. F., Six years of robots. Advances in Laboratory
Automation Robotics (Zymark Corporation, Hopkinton, Mas-
sachusetts, 1991), 109.